Catalog No.
PMC10001
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse TP53/p53 (Met1-Asp390).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Antigen NY-CO-13, Cellular tumor antigen p53, P53, Tumor suppressor p53, TP53, Phosphoprotein p53
Purification
Purified by antigen affinity column.
Accession
P02340
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma., PMID:40516820
The Intrabody Against Murine Double Minute 2 via a p53-Dependent Pathway Induces Apoptosis of Cancer Cell., PMID:40508092
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies., PMID:40497952
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331
Focal High-Grade Areas with a Tumor-in-Tumor Pattern: Another Feature of Pediatric DICER1-Associated Thyroid Carcinoma?, PMID:40448797
Exceptional Long-term Response to Immunotherapy in an African American Man With STK11/TP53/RB1-Mutated Metastatic Lung Adenocarcinoma., PMID:40448514
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies., PMID:40435909
Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas., PMID:40416001
Immunohistochemical and molecular evolutionary features of jejunoileal adenocarcinoma unveiled through comparative analysis with colorectal adenocarcinoma., PMID:40403397
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer., PMID:40393272
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia., PMID:40382198
Molecular and clinicopathological characteristics of invasive breast cancers with HER2-ultralow expression., PMID:40379141
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era., PMID:40361510
FRα expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates., PMID:40344965
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma., PMID:40278919
PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer., PMID:40273724
Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non-Small Cell Lung Cancer., PMID:40239138
Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine., PMID:40237885
Bioconjugates of photon-upconversion nanoparticles with antibodies for the detection of prostate-specific antigen and p53 in heterogeneous and homogeneous immunoassays., PMID:40231544
Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma., PMID:40215977
Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma., PMID:40204067
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272
Pancreatic Cancer: Pathogenesis and Clinical Studies., PMID:40182139
GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms., PMID:40168773
Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis., PMID:40167580
[Relapse-related candidate genes and their clinicopathological connections of diffuse large B cell lymphoma]., PMID:40159024
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer., PMID:40148708
Mantle cell lymphoma: from pathogenesis to treatment for 2024 and beyond., PMID:40146175
Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review., PMID:40127387
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment., PMID:40111422
Fc fragment of IgG binding protein suppresses tumor growth by stabilizing wild type P53 in colorectal cancer cells., PMID:40108539
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges., PMID:40105906
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes., PMID:40080442
Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy., PMID:40066747
Case Report: Complete response to four cycles of camrelizumab in a PD-L1 negative patient with advanced oral squamous cancer., PMID:40066447
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies., PMID:40045912
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies., PMID:40038334
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)., PMID:40036771
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma., PMID:40030008
Gastric-type endocervical adenocarcinoma, superficial myofibroblastoma, sex cord-stromal tumors, and HSIL in Peutz-Jeghers syndrome: a rare case report, genetic characterization, and review of literature., PMID:40018404
Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents., PMID:40011029
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study., PMID:40009500
An Anti-CD147 Antibody-Drug Conjugate Mehozumab-DM1 is Efficacious Against Hepatocellular Carcinoma in Cynomolgus Monkey., PMID:39985225
miRNome analysis reveals mir-155-5p as a protective factor to dengue infection in a resistant Thai cohort., PMID:39976655
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia., PMID:39976417
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia., PMID:39955432
Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma., PMID:39939142
For research use only. Not for human or drug use.
